Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAD0004J08 in Early Mild-to-Moderate COVID-19
NCT04952805Phase 3Unknown
- Sponsor
- Toscana Life Sciences Sviluppo
- Start
- Jun 2021
- Primary completion
- Mar 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of MAbCo19 in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Toscana Life Sciences Sviluppo. Primary endpoints: Severe (Grade 3) unsolicited AEs and/or serious unsolicited AEs at Day 0 and Time to SARS-CoV-2 clearance in the URT at Day 168. Status: unknown.
02
Drugs
MAbCo19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04952805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04952805.